Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung
Status:
Terminated
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize bacterial diversity and richness in the sputum
of cystic fibrosis patients treated with every-other-month TOBI™ Podhaler™ and continuous
alternating therapy with TOBI™ Podhaler and colistimethate (Colistin).